# Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

> **NCT02156674** · NA · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 1 (actual)

## Conditions studied

- Maroteaux-Lamy Syndrome

## Interventions

- **DRUG:** Naglazyme®

## Key facts

- **NCT ID:** NCT02156674
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01-26
- **Primary completion:** 2019-12-01
- **Final completion:** 2019-12-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2020-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02156674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02156674, "Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02156674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*